Get the Stockscreener App
10.39
1.05%
-0.11
Adaptive Biotechnologies Corp stock is traded at $10.39, with a volume of 1.44M.
It is down -1.05% in the last 24 hours and down -0.76% over the past month.
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).
See More
Previous Close:
$10.50
Open:
$10.66
24h Volume:
1.44M
Relative Volume:
0.68
Market Cap:
$1.58B
Revenue:
$177.28M
Net Income/Loss:
$-195.24M
P/E Ratio:
-7.7537
EPS:
-1.34
Net Cash Flow:
$-114.54M
1W Performance:
-12.10%
1M Performance:
-0.76%
6M Performance:
+52.57%
1Y Performance:
+145.63%
1-Day Range:
$10.25
$10.77
1-Week Range:
$10.25
$11.90
52-Week Range:
$3.845
$12.43
Adaptive Biotechnologies Corp Stock (ADPT) Company Profile
Name
Adaptive Biotechnologies Corp
Sector
Industry
Phone
206-659-0067
Address
1165 EASTLAKE AVE E, SEATTLE, WA
Compare ADPT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ADPT
Adaptive Biotechnologies Corp
|
10.39 | 1.80B | 177.28M | -195.24M | -114.54M | -1.34 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.81 | 120.40B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
542.52 | 61.30B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.53 | 41.06B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
564.59 | 34.29B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
294.55 | 27.09B | 3.81B | -644.79M | -669.77M | -6.24 |
Adaptive Biotechnologies Corp Stock (ADPT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-18-25 | Initiated | Craig Hallum | Buy |
| Mar-21-25 | Upgrade | Goldman | Neutral → Buy |
| Jul-05-23 | Resumed | JP Morgan | Overweight |
| Jan-05-23 | Initiated | Scotiabank | Sector Outperform |
| Dec-21-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Aug-25-22 | Initiated | Credit Suisse | Underperform |
| Jun-03-22 | Initiated | Piper Sandler | Neutral |
| Feb-16-22 | Reiterated | BTIG Research | Buy |
| Feb-16-22 | Reiterated | BofA Securities | Buy |
| Feb-16-22 | Reiterated | Goldman | Neutral |
| Feb-16-22 | Reiterated | JP Morgan | Overweight |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Mar-03-21 | Downgrade | Goldman | Buy → Neutral |
| Oct-08-20 | Resumed | BTIG Research | Buy |
| Sep-09-20 | Initiated | Morgan Stanley | Equal-Weight |
| Jun-03-20 | Initiated | Goldman | Buy |
| Jul-23-19 | Initiated | BTIG Research | Buy |
| Jul-22-19 | Initiated | BofA/Merrill | Buy |
| Jul-22-19 | Initiated | Cowen | Outperform |
| Jul-22-19 | Initiated | Goldman | Neutral |
| Jul-22-19 | Initiated | Guggenheim | Buy |
| Jul-22-19 | Initiated | William Blair | Outperform |
View All
Adaptive Biotechnologies Corp Stock (ADPT) Latest News
Principal Financial Group Inc. Purchases 141,691 Shares of Adaptive Biotechnologies Corporation (NASDAQ:ADPT) - Defense World
Cerity Partners LLC Sells 21,433 Shares of Adaptive Biotechnologies Corporation (NASDAQ:ADPT) - Defense World
Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World
Is Adaptive Biotechnologies Corporation a good long term investmentPhenomenal capital gains - Jammu Links News
What analysts say about Adaptive Biotechnologies Corporation stockSky-high return potential - Jammu Links News
Teacher Retirement System of Texas Acquires New Position in Adaptive Biotechnologies Corporation (NASDAQ:ADPT) - Defense World
Adaptive Biotechnologies Corporation to Announce Second Quarter 2025 Financial Results on August 5, 2025 - Quiver Quantitative
Adaptive Biotechnologies to Report Second Quarter 2025 Financial Results on August 5, 2025 - Yahoo Finance
How Adaptive Biotechnologies Corporation stock performs during market volatilityTrade Ready Signal - Newser
What makes Adaptive Biotechnologies Corporation stock price move sharplyHigh Confidence Trade Setups - Newser
Wealth Enhancement Advisory Services LLC Invests $87,000 in Adaptive Biotechnologies Corporation (NASDAQ:ADPT) - Defense World
Are Medical Stocks Lagging Adaptive Biotechnologies (ADPT) This Year? - Yahoo Finance
Adaptive Biotechnologies and Flatiron Health Announce Integration of clonoSEQ® MRD Testing into OncoEMR® - Yahoo Finance
Adaptive Biotechnologies Corporation(NasdaqGS:ADPT) added to Russell 3000 Growth Index - MarketScreener
Adaptive Biotechnologies (ADPT) Surges 12.5%: Is This an Indication of Further Gains? - Yahoo Finance
Adaptive Biotechnologies stock hits 52-week high at 10.88 USD By Investing.com - Investing.com South Africa
Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Given Average Rating of “Moderate Buy” by Brokerages - Defense World
Cathie Wood's Ark Invest Adds Airbnb, AMD, Shopify To Portfolio, Slashes Stake In Circle Internet - Benzinga
Rhumbline Advisers Raises Stake in Adaptive Biotechnologies Corporation (NASDAQ:ADPT) - Defense World
Cathie Wood’s ARK buys BWX stock, sells Adaptive Biotech - Investing.com
Adaptive Biotechnologies (ADPT) Initiates Coverage with Buy Rating | ADPT Stock News - GuruFocus
Adaptive Biotechnologies (ADPT) Sees Positive Growth Prospects | - GuruFocus
Assessing Adaptive Biotechnologies: Insights From 5 Financial Analysts - Nasdaq
Adaptive Biotechnologies (ADPT) Receives New Buy Rating and Pric - GuruFocus
Adaptive Biotechnologies reports annual meeting outcomes By Investing.com - Investing.com Nigeria
Adaptive Biotechnologies reports annual meeting outcomes - Investing.com
Adaptive Biotechnologies Co. (NASDAQ:ADPT) Shares Bought by California State Teachers Retirement System - Defense World
Adaptive Biotechnologies at Goldman Sachs Conference: Strong Q1 Performance and Strategic Growth - Investing.com
Is Adaptive Biotechnologies (ADPT) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
118,593 Shares in Adaptive Biotechnologies Co. (NASDAQ:ADPT) Acquired by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - Defense World
Squarepoint Ops LLC Raises Position in Adaptive Biotechnologies Co. (NASDAQ:ADPT) - Defense World
Nasdaq Today Adaptive Biotechnologies’ Role in Innovation Kalkine - Kalkine Media
ADPT stock soars to 52-week high, hits $10.28 amid surge - Investing.com India
Two Sigma Advisers LP Has $309,000 Holdings in Adaptive Biotechnologies Co. (NASDAQ:ADPT) - Defense World
Two Sigma Investments LP Has $1.10 Million Position in Adaptive Biotechnologies Co. (NASDAQ:ADPT) - Defense World
Adaptive Biotechnologies Co. (NASDAQ:ADPT) Shares Sold by Bank of America Corp DE - Defense World
Cathie Wood’s ARK buys Guardant Health, sells Adaptive Biotechnologies stock - Investing.com Nigeria
Adaptive Biotechnologies Co. (NASDAQ:ADPT) Shares Purchased by MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. - Defense World
Cathie Wood's Ark Invest Continues To Offload Tesla As Elon Musk Moves On From Trump Administration - Benzinga
Adaptive Biotechnologies (ADPT) Showcases clonoSEQ Test Advances at Key Conferences | ADPT Stock News - GuruFocus
Adaptive Biotechnologies Highlights New Data at 2025 ASCO Annual Meeting and EHA 2025 Congress Demonstrating How clonoSEQ® MRD Assessment is Optimizing Patient Care and Drug Development in Lymphoid Cancers - The Manila Times
Adaptive Biotechnologies’ MRD test featured in cancer studies - Investing.com
Adaptive Biotechnologies Co. (NASDAQ:ADPT) Receives Consensus Recommendation of “Moderate Buy” from Brokerages - Defense World
BNP Paribas Financial Markets Reduces Stock Position in Adaptive Biotechnologies Co. (NASDAQ:ADPT) - Defense World
Cathie Wood’s ARK buys CRISPR, sells Adaptive Biotech stock By Investing.com - Investing.com Nigeria
Cathie Wood’s ARK buys CRISPR, sells Adaptive Biotech stock - Investing.com
Adaptive Biotechnologies to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference - The Manila Times
Is Adaptive Biotechnologies (ADPT) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Janus Henderson Group PLC Buys Shares of 46,900 Adaptive Biotechnologies Co. (NASDAQ:ADPT) - Defense World
Catherine Wood Reduces Stake in Adaptive Biotechnologies Corp - GuruFocus
Adaptive Biotechnologies Corp Stock (ADPT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.59%
0.34%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):